Latest AlzeCure Pharma News & Updates

See the latest news and media coverage for AlzeCure Pharma. We track all announcements, press releases, and industry mentions in real time, all in one place.

AlzeCure Pharma

Swedish pharmaceutical company developing treatments for Alzheimer's and related disorders

alzecurepharma.se

Headquarters: Stockholm, Sweden
Founded year: 2016
Company type: Public company
Number of employees: 15–50

Last updated Today

Latest news about AlzeCure Pharma

In short: AlzeCure Pharma entered a global collaboration and licensing deal with Eli Lilly for its Alzheimer's treatment, potentially worth over $1 billion.

Company announcements

June 16 AlzeCure Pharma

AlzeCure Pharma announces positive Phase Ib results for NeuroRestore ACD856

The study met its safety and tolerability endpoints, with increased drug concentration in blood and cerebrospinal fluid, supporting dose selection for Phase II.

June 16 AlzeCure Pharma

AlzeCure Pharma's rights issue subscription period begins today

The offering aims to raise approximately SEK 30.1 million and is fully secured by major shareholders.

June 9 AlzeCure Pharma

AlzeCure Pharma partners with Lilly for Alzheimer's project

The deal includes $10M upfront, milestones up to $1B, and royalties for Alzstatin ACD680.

May 26 AlzeCure Pharma

AlzeCure Pharma announces notice of annual general meeting

The meeting will be held on June 29, 2026, in Stockholm, with proposals for board elections and authorization for new share issues.

Media coverage

June 16 Yahoo Finance

Positive Results From The Phase Ib Clinical Study of NeuroRestore ACD856, Under Development for Alzheimer's

STOCKHOLM, SE / ACCESS Newswire / June 16, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), a biotech company that develops candidate drugs for diseases affecting...

June 9 Dagens industri

Billion payment beckons for small research company: 'Looks promising'

The small research company Alzecure Pharma, with a market value of 159 million kronor, has entered into an agreement with the American giant Eli Lilly which...

June 9 Reuters

AlzeCure signs collaboration, out-licensing deal with Lilly for Alzheimer's drug

AlzeCure Pharma said on Tuesday it had entered a collaboration and out-licensing agreement with ‌Eli Lilly for the global rights of an Alzheimer's treatment in...

May 6 FinanzNachrichten

AlzeCure Pharma: New scientific Article Published on TrkA-NAM ACD137 Against Osteoarthritic Pain

STOCKHOLM, SE / ACCESS Newswire / May 6, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), a biotech company that develops candidate drugs for diseases affecting...

Never miss news about AlzeCure Pharma

Track AlzeCure Pharma and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

AlzeCure Pharma competitors & trending companies

Browse news for competitors to AlzeCure Pharma and other trending companies.